From biomarker discovery and validation to trial design and label expansion, QIAGEN Real-World Insights (RWI) helps you bridge the gap between actionable insight and real-world action.
The majority of cancer patients today are diagnosed and treated outside the context of clinical research—that is, in the real world.
To improve the efficiency, efficacy, and cost of clinical trials, pharmaceutical companies are using real-world data at each stage of the drug development process.
QIAGEN’s RWI portfolio combines robust real-world data from over 200,000 cancer cases and advanced analytics to shorten development timelines, optimize study designs, and improve patient outcomes.
Join us on Tuesday, June 9 at 11 AM ET for a live interactive webcast, where the QIAGEN Real-World Insights team will interview Dr. Anna Pokorska-Bocci, PhD, of Debiopharm International. The conversation will address the challenges of developing oncology targeted therapies and how Debiopharm was able to accelerate drug development with customized analyses and solutions from QIAGEN Real-World Insights. Register here.
QIAGEN RWI is a professional and personalized service empowering pharmaceutical companies to better understand their target populations. RWI helps you get drugs to market faster, expand their usage to new indications, and confidently answer critical questions, such as:
Deciding which biomarkers to include and what technology to use is neither simple nor straight forward. Clinical relevance, reliability, and practicality are of critical importance when selecting biomarkers.
Using robust genomic sequencing data and molecular testing trends, QIAGEN RWI analyses can identify, prioritize and validate biomarkers of therapeutic response and resistance to optimize your drug development strategy.
Designing an effective trial begins with defining the patient cohort and designing a CDx—a lengthy and iterative process that requires extensive research, testing, and refinement.
QIAGEN RWI provides the ability to rapidly mine real-world data and link genomic information to specific phenotypes to design a trial tailored to the desired patient cohort and optimized for the highest likelihood of success.
Biomarkers in a patient’s tumor are becoming increasingly critical in determining the appropriate treatment. As more patients undergo diagnostic sequencing, vast amounts of genomic data are being collected, enabling a paradigm shift in how drugs are developed and trials designed.
QIAGEN RWI provides real-world molecular profiling and drug response data from over 160,000 individual cancer cases to help you better understand the genomic characteristics of your target population.
The prevalence of cancer biomarkers detected in the laboratory differs from what is observed at the bedside. Real-world data helps you better understand the actual numbers of patients with a particular cancer type and where and for which biomarkers they are being tested.
Providing information on current molecular testing trends, QIAGEN RWI allows for an expanded view of cancer indications to be evaluated for your drug for maximum reach and success.
Create and deliver bespoke drug development projects with a range of flexible options and services tailored to your unique requirements. Our specialized team works with you to develop the informatics tools and evidence resources you need to get consistent, reliable and actionable results through all phases of your study.
QIAGEN’s RWI portfolio delivers real-world data from over 200,000 cancer cases to enable better decisions faster in early drug and test development.
To access RWI, you can:
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.
From research to regulatory submission, we help you connect data to insight for faster drug discovery and optimized trial design
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses